May 07, 2020
Duchenne Muscular Dystrophy Market is Anticipated to Grow With a CAGR of 31.8% for the Study Period of 2017-2030: DelveInsight
May 05, 2020
FDA Clears LPCN 1148 IND Application for Phase 2 Cirrhosis Trial
May 04, 2020
Viriom Announces Initiation of Phase 2 Study Investigating Efficacy of Intramuscular Long-Acting Injectable Nanoformulation of VM1500A in HIV-Infected Patients
Apr 17, 2020
U.S. FDA Denies Clarus's Oral Testosterone Ester Citizen Petition
Apr 14, 2020
Granata Bio and IBSA Group Announce Strategic Partnership
Mar 06, 2020
FDA Approves New Treatment for Adults with Cushing's Disease
Feb 12, 2020
ANI Announces Launch of Sulfamethoxazole and Trimethoprim Oral Suspension USP 200 mg/40 mg per 5 mL
Dec 12, 2019
Kindred Biosciences Announces European Commission Approval of Mirataz® 20 mg/g Transdermal Ointment for Cats Experiencing Poor Appetite and Weight Loss
Oct 03, 2019
ANI Announces Positive Clinical Results from Cortrophin® Gel Cortisol Response Study
Sep 16, 2019
Exeltis USA, Inc. Announces the Launch of Slynd(TM)(drospirenone) tablets, 4 mg, the First and Only Progestin-Only Pill Providing Pregnancy Prevention with a 24-hour missed pill window and 24/4 Dosing Regimen
Jun 18, 2019
Organic Conceptions and Proov Form Strategic Alliance that Brings Hope to Couples Struggling with Infertility
Jun 07, 2019
PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age
Jun 06, 2019
Exeltis USA, Inc. Announces the Approval of Slynd(TM), the First and Only Progestin-Only Pill Providing Pregnancy Prevention with a 24/4 Dosing Regimen and 24-hour Missed Pill Window
Mar 29, 2019
Pharmascience Inc. launches (Pr)pms-PROGESTERONE 200 mg capsule indicated as an adjunct to postmenopausal estrogen replacement therapy
Mar 25, 2019
Slayback Pharma announces approval of Hydroxyprogesterone Caproate Injection, USP 250 mg/ 1 mL in a single-dose vial, generic equivalent of Makena® Injection 250 mg/ 1 mL
Mar 07, 2019
Forendo Pharma Successfully Completes Phase 1a Clinical Trial of FOR-6219 for the Treatment of Endometriosis
Mar 05, 2019
Enteris BioPharma Supports Endometriosis Awareness Month
Jan 21, 2019
Slayback Pharma announces launch of Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 mL in a multi-dose vial, the first generic equivalent of Makena® Injection 1,250 mg/ 5 mL multi-dose vial
Jan 17, 2019
Parent Project Muscular Dystrophy Publishes 10 Year Registry Report
Jan 08, 2019
Calliditas Therapeutics Appoints Andrew Udell to VP Commercial, North America